Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: A RENAPE study.
Details
Serval ID
serval:BIB_EA604CC9FB90
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: A RENAPE study.
Journal
European journal of surgical oncology
Working group(s)
French RENAPE Network
Contributor(s)
Abba J., Abboud K., Alyami M., Arvieux C., Bakrin N., Balagué G., Barrau V., Bereder J.M., Berton-Rigaud I., Bonnefoy I., Bouzard D., Bricault I., Brigand C., Carrère S., de Chaisemartin C., Chassang M., Chevallier A., Courvoisier T., Dohan A., Dromain C., Dubreuil J., Dumont F., Eveno C., Faruch-Bilfeld M., Ferron G., Fournier L., Gagniere J., Geffroy D., Ghouti L., Gladieff L., Glehen O., Goéré D., Guibal A., Guilloit J.M., Guyon F., Heyd B., Hoeffel C., Hordonneau C., Jourdan-Enfer P., Kaci R., Kianmanesh R., Labbé-Devilliers C., Lacroix J., Lelong B., Leroux-Broussier A., Lherm Y., Lo Dico R., Lorimier G., Malhaire C., Marchal F., Mariani P., Mathiotte E., Meeus P., Msika S., Nadeau C., Ortega-Deballon P., Passot G., Pellet O., Peyrat P., Pezet D., Pirro N., Pocard M., Poizat F., Porcheron J., Poulet A., Quenet F., Rat P., Rousselot P., Senellart H., Serrano M., Servois V., Sgabura O., Skanjeti A., Svrcek M., Tetreau R., Thibaudeau E., Touchefeu Y., Tuech J.J., Vaudoyer D., Velasco S., Wernert R., Zinzindohoue F.
ISSN
1532-2157 (Electronic)
ISSN-L
0748-7983
Publication state
Published
Issued date
10/2017
Peer-reviewed
Oui
Volume
43
Number
10
Pages
1915-1923
Language
english
Notes
Publication types: Journal Article ; Observational Study
Publication Status: ppublish
Publication Status: ppublish
Abstract
Epithelioid peritoneal malignant mesothelioma (EPMM) is the most common subtype of this aggressive tumor. We compared two antibodies against PD-L1, a recent theranostic biomarker, and evaluated the prognostic value of PD-L1 expression by mesothelial and immune cells in EPMM.
Immunohistochemistry was performed on 45 EPMM. Clinical and pathological data were extracted from the RENAPE database. Using E1L3N and SP142 clones, inter-observer agreement, PD-L1 expression by mesothelial and immune cells and inter-antibody agreement were evaluated. The prognostic relevance of PD-L1 expression was evaluated in 39 EPMM by univariate and multivariate analysis of overall survival (OS) and progression-free survival (PFS).
Inter-observer agreement on E1L3N immunostaining was moderate for mesothelial and immune cells, and fair for mesothelial and poor for immune cells using SP142. Using E1L3N, 31.1% of mesothelial and 15.6% of immune cells expressed PD-L1, and 22.2% of mesothelial and 26.7% of immune cells using SP142. Inter-antibody agreement was moderate. In most positive cases, 1-5% of tumor cells were positive. Using E1L3N, PD-L1 expression by lymphocytes was associated with better OS and PFS by both univariate and multivariate analysis. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy predicted better prognosis than other treatments. Solid subtype was an independent prognostic factor for worse OS.
E1L3N appeared easier to use than SP142 to evaluate PD-L1 expression. A minority of EPMM expressed PD-L1, and only a few cells were positive. PD-L1 expression by immune cells evaluated with E1L3N was an independent prognostic factor in EPMM.
Immunohistochemistry was performed on 45 EPMM. Clinical and pathological data were extracted from the RENAPE database. Using E1L3N and SP142 clones, inter-observer agreement, PD-L1 expression by mesothelial and immune cells and inter-antibody agreement were evaluated. The prognostic relevance of PD-L1 expression was evaluated in 39 EPMM by univariate and multivariate analysis of overall survival (OS) and progression-free survival (PFS).
Inter-observer agreement on E1L3N immunostaining was moderate for mesothelial and immune cells, and fair for mesothelial and poor for immune cells using SP142. Using E1L3N, 31.1% of mesothelial and 15.6% of immune cells expressed PD-L1, and 22.2% of mesothelial and 26.7% of immune cells using SP142. Inter-antibody agreement was moderate. In most positive cases, 1-5% of tumor cells were positive. Using E1L3N, PD-L1 expression by lymphocytes was associated with better OS and PFS by both univariate and multivariate analysis. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy predicted better prognosis than other treatments. Solid subtype was an independent prognostic factor for worse OS.
E1L3N appeared easier to use than SP142 to evaluate PD-L1 expression. A minority of EPMM expressed PD-L1, and only a few cells were positive. PD-L1 expression by immune cells evaluated with E1L3N was an independent prognostic factor in EPMM.
Keywords
Antibodies, Neoplasm/immunology, Antibodies, Neoplasm/metabolism, Antigens, CD274/biosynthesis, Antigens, CD274/immunology, Biomarkers, Tumor/immunology, Biomarkers, Tumor/metabolism, Female, Follow-Up Studies, France/epidemiology, Humans, Immunity, Cellular, Immunohistochemistry/methods, Lymphocytes/immunology, Lymphocytes/metabolism, Male, Mesothelioma/immunology, Mesothelioma/metabolism, Mesothelioma/mortality, Middle Aged, Peritoneal Neoplasms/immunology, Peritoneal Neoplasms/metabolism, Peritoneal Neoplasms/mortality, Prognosis, Retrospective Studies, Survival Rate/trends, Epithelioid subtype, Immunohistochemistry, PD-L1, Peritoneal mesothelioma, Survival
Pubmed
Create date
07/09/2017 15:36
Last modification date
20/08/2019 17:12
Usage data
